Ovid Therapeutics (OVID) Net Cash Flow Growth (3y) (2019 - 2026)
Powered by 
Analysis
Ovid Therapeutics (OVID) Net Cash Flow Growth (3y) (2019 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | NCF Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 663.08 Bn | 642.33 Bn | 17.26 Bn | 38.95% |
| 2 | AbbVie | 453.04 Bn | 446.51 Bn | 12.70 Bn | -49.89% |
| 3 | Merck | 370.87 Bn | 363.78 Bn | 12.21 Bn | 33.59% |
| 4 | Novartis Ag | 305.29 Bn | 298.00 Bn | 11.24 Bn | 38.53% |
| 5 | Pfizer | 162.10 Bn | 150.70 Bn | 10.94 Bn | -51.84% |
| 6 | Sanofi | 53.95 Bn | 46.98 Bn | 10.79 Bn | 1.06% |
| 7 | Revolution Medicines | 45.00 Bn | 45.00 Bn | - | - |
| 8 | BeOne Medicines | 40.49 Bn | 35.39 Bn | 1.53 Bn | 106.37% |
| 9 | Incyte | 25.47 Bn | 20.94 Bn | 1.57 Bn | 18.67% |
| 10 | Ovid Therapeutics | 517.32 Mn | 400.10 Mn | - | -126.72% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -126.72% |
| Mar 31, 2026 | 64.56% |
| Dec 31, 2025 | 18.34% |
| Sep 30, 2025 | 18.76% |
| Jun 30, 2025 | 27.60% |
| Mar 31, 2025 | 37.47% |
| Dec 31, 2024 | 43.20% |
| Sep 30, 2024 | -12.21% |
| Jun 30, 2024 | 62.78% |
| Mar 31, 2024 | -71.49% |
| Dec 31, 2023 | -27.02% |
| Sep 30, 2023 | -32.21% |
| Jun 30, 2023 | -14.92% |
| Mar 31, 2023 | 48.11% |
| Dec 31, 2022 | -74.97% |
| Sep 30, 2022 | -15.47% |
| Jun 30, 2022 | -134.93% |
| Mar 31, 2022 | -46.85% |
| Dec 31, 2021 | -58.96% |
| Sep 30, 2021 | -48.91% |